SRRK peer analysis
Scholar Rock (SRRK) against its competitors: price, today's move, 1-year return and market value side by side.
SRRK and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BBIO BridgeBio Pharma | $74.31 | -0.85% | 17.26% | $14.60B |
| BEAM Beam Therapeutics | $25.86 | -5.03% | 8.66% | $2.81B |
| DYN Dyne Therapeutics | $17.30 | 3.68% | -26.52% | – |
| EWTX Edgewise Therapeutics | $38.13 | -1.97% | 104.26% | – |
| IONS Ionis Pharmaceuticals | $41.21 | -5.31% | -44.44% | $7.23B |
| MAZE Maze Therapeutics | $30.48 | -3.18% | -8.25% | – |
| PTCT PTC Therapeutics | $60.84 | 1.45% | -10.67% | $5.01B |
| SRPT Sarepta Therapeutics | $18.32 | -1.64% | -21.23% | $1.97B |
| STOK Stoke Therapeutics | $26.43 | 0.53% | -16.62% | $1.70B |
| XENE Xenon Pharmaceuticals | $37.59 | 0.48% | -11.91% | $3.62B |
| SRRK Scholar Rock | $42.91 | -2.26% | 46.10% | $5.35B |
- SRRK's peers: BBIO (BridgeBio Pharma), BEAM (Beam Therapeutics), DYN (Dyne Therapeutics), EWTX (Edgewise Therapeutics), IONS (Ionis Pharmaceuticals), MAZE (Maze Therapeutics), PTCT (PTC Therapeutics), SRPT (Sarepta Therapeutics).
Updated 2026-11-03 02:04 UTC